SEARCH

SEARCH BY CITATION

References

  • 1
    Heintges T, Wands JR. Hepatitis C virus: Epidemiology and transmission. Hepatology 1997; 26: 521526.
  • 2
    Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11: 479489.
  • 3
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S35S46.
  • 4
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 5
    Berenguer M. Hepatitis C after liver transplantation: Risk factors, outcomes, and treatment [abstract]. Curr Opin Organ Transplant 2005; 10: 8189.
  • 6
    Bahr MJ, Manns MP. Changing faces—Natural course and treatment of hepatitis C after liver transplantation. J Hepatol 2004; 40: 699701.
  • 7
    Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004; 24 (Suppl 2): 7988.
  • 8
    Rosen HR, O'Reilly PM, Shackleton CR et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996; 62: 17731776.
  • 9
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730739.
  • 10
    Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004; 4: 717.
  • 11
    Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226231.
  • 12
    Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673684.
  • 13
    Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004; 17: 363371.
  • 14
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 15
    Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 16
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188.
  • 17
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676680.
  • 18
    Ozminkowski RJ, Wortman PM, Roloff DW. Inborn/outborn status and neonatal survival: A meta-analysis of non-randomized studies. Stat Med 1988; 7: 12071221.
  • 19
    Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 20
    Alberti AB, Belli LS, Airoldi A et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001; 7: 870876.
  • 21
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863869.
  • 22
    Kornberg A, Hommann M, Tannapfel A et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001; 1: 350355.
  • 23
    De Vera ME, Smallwood GA, Rosado K et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678686.
  • 24
    Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 12531258.
  • 25
    Lavezzo B, Franchello A, Smedile A et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247252.
  • 26
    Narayanan Menon KV, Poterucha JJ, El Amin OM et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623629.
  • 27
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 28
    Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642650.
  • 29
    Nair S, Khan S, Loss G et al. Treatment of recurrent hepatitis C in liver transplant recipients: Is there any histologic benefit? Liver Transpl 2003; 9: 354359.
  • 30
    Giostra E, Kullak-Ublick GA, Keller W et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17: 169176.
  • 31
    Berenguer M, Prieto M, Palau A et al. Recurrent hepatitis C genotype 1b following liver transplantation: Treatment with combination interferon–ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 12071212.
  • 32
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict CA, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166173.
  • 33
    Mukherjee S, Lyden E, McCashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: Cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20: 198203.
  • 34
    Targhetta S, Burra P, Popovic A et al. Natural alpha-IFN in HCV recurrence after liver transplantation. Transplant Proc 2001; 33: 14571458.
  • 35
    Dumortier J, Scoazec JY, Berger F, Boillot O. Recurrence of hepatitis C after liver transplantation: Follow-up and treatment. Transplant Proc 2002; 34: 779781.
  • 36
    Yedibela S, Schuppan D, Muller V et al. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005; 25: 717722.
  • 37
    Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577582.
  • 38
    Willner I, Chavin K, Rogers J, Baliga P, Reuden A. Combination interferon–ribavirin (IFN–RIB) is ineffective and poorly tolerated by liver transplant (LT) recipients with genotype 1 recurrent hepatitis C [abstract]. Hepatology 2000; 32 [4(Pt2)]: 291A.
  • 39
    Gordon FD, Davis C, Morin D et al. Sustained response with interferon/ribavirin for recurrent hepatitis C after liver transplantation [abstract]. Am J Transplant 2001; 1 (S1): 207.
  • 40
    Firpi RJ, Abdelmalek MF, Lauwers GY, Nelson DR, Soldevila-Pico C, Davis GL. Interferon alfa and ribavirin for orthotopic liver transplant recipients with recurrent hepatitis C [abstract]. Gastroenterology 2000; 118: 1018.
  • 41
    Bizollon T, Palazzo U, Chevallier M, Ducerf C, Trepo C. HCV recurrence after OLT: A pilot study of ribavirin therapy following initial combination with IFN [abstract]. Hepatology 1996; 24: 293A.
  • 42
    Bizollon T, Palazzo U, Ahmed SN et al. HCV recurrence after liver transplantation: Risk factors and response to interferon (IFN)–ribavirin [abstract]. Gastroenterology 1996; 110: A1152.
  • 43
    Firpi RJ, Nelson DR, Soldevila C et al. Combination of interferon alfa 2B and ribavirin in liver transplant recipients with histologic recurrent hepatitis C [abstract]. Gastroenterology 2001; 120: A93.
  • 44
    Belli LS, Alberti AB, Airoldi A et al. IFN/Riba treatment for recurrent hepatitis C after liver transplantation: Progression of hepatic fibrosis is favourably affected in both virological and biochemical sustained responders [abstract]. J Hepatol 2004; 40 (S1): 39.
  • 45
    Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 30423044.
  • 46
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 47
    Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190194.
  • 48
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 49
    Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 50
    Planas JM, Gonzalez ER, Grana EB et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37: 22072208.
  • 51
    Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359365.
  • 52
    Bahra M, Neumann UP, Berg T, Neuhaus R, Langrehr JM, Neuhaus P. Pegylated interferon alfa-2b plus ribavirin in patients with hepatitis C reinfection after OLT [abstract]. Am J Transplant 2003; 3 (S5): 432.
  • 53
    Lavezzo B, Franchello A, Smedile A et al. Preliminary results of naive combination therapy with 12 KDA PEG-IFN a-2B and ribavirin in recurrent hepatitis C after liver transplantation [abstract]. J Hepatol 2003; 38 (S2): 42.
  • 54
    Samuel D. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin [abstract]. Hepatology 2003; 34 [4(S1)]: 531A.
  • 55
    Lorenzini S, Biselli M, Gramenzi A et al. Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation [abstract]. J Hepatol 2004; 40 (S1): 144.
  • 56
    Neff G, Montalbano M, Ozden N et al. Treatment of naive hepatitis C recurrence (HCV-R) in liver transplant recipients with pegylated interferon alpha-2B and ribavirin [abstract]. J Hepatol 2003; 38 (S2): 160.
  • 57
    Kontorinis N, Elhajj N, Agarwal K et al. Improved efficacy and tolerability in treating post-transplant HCV utilizing an escalating regimen of pegylated interferon-a-2a and ribavirin with hematopoietic growth factors: A prospective study [abstract]. Gastroenterology 2004; 126 (S2) A664.
  • 58
    Gordon FD, Morin D, Davis C et al. High sustained virological response (SVR) in HCV treatment with peginterferon-alfa 2B (PEG) and ribavirin (RBV) after liver transplantation (LT) [abstract]. Am J Transplant 2005; 5 (S11): 181.
  • 59
    Martinez AE, Smallwood GA, Devine RM et al. Histopathologic assessment of post-orthotopic liver transplant (OLT) recurrent hepatitis C (HCV) in patients treated with pegylated interferon and ribavirin [abstract]. Am J Transplant 2005; 5 (S11): 206.
  • 60
    Samanta A, Mandalapu A, Fisher A et al. Treatment with combination peginterferon alfa-2B and ribavirin of recurrent hepatitis C in liver transplant recipients nonresponsive to interferon alfa-2b and ribavirin [abstract]. Gastroenterology 2005; 128 (S2): 128.
  • 61
    Kontorinis N, Elhajj N, Agarwal K et al. Treatment of post-transplant HCV with pegylated interferon alfa 2A and ribavirin (RBV)—Effect of pre-treatment fibrosis stage [abstract]. J Hepatol 2005; 42 (S2): 53.
  • 62
    Martini S, Lavezzo B, Saettone S et al. Pegylated interferon (PEG-IFN) alfa 2B + ribavirin (RB) in the treatment of post-liver transplant (LT) recurrent hepatitis C [abstract]. J Hepatol 2005; 42 (S2): 53.
  • 63
    Picciotto FP, Lanza AG, De Luca M et al. Pegylated-interferon alpha-2B plus ribavirin in the treatment of HCV reinfection after liver transplantation—Experience of a single centre [abstract]. J Hepatol 2005; 42 (S2): 58.
  • 64
    Mazzaferro V, Regalia E, Pulvirenti A et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997; 29: 519521.
  • 65
    Sugawara Y, Makuuchi M, Matsui Y et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 13081311.
  • 66
    Mazzaferro V, Tagger A, Schiavo M et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 13551357.
  • 67
    Reddy R, Fried M, Dickson R et al. Interferon alfa-2b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: Results of a multicenter, randomized trial [abstract]. Gastroenterology 2002; 122: 199A.
  • 68
    Nair S, Eason J, Loss G et al. Early treatment of recurrent hepatitis C in liver transplant recipients: Is the virological and histological response better?[abstract]. Gastroenterology 2002; 122: 633A.
  • 69
    Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review. Health Technol Assess 2000; 4: 167.
  • 70
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004; 8: iii-125.
  • 71
    Bizollon T, Ahmed SN, Radenne S et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon–ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 72
    Willems M, Metselaar HJ, Tilanus HW, Schalm SW, De Man RA. Liver transplantation and hepatitis C. Transpl Int 2002; 15: 6172.
  • 73
    Magnone M, Holley JL, Shapiro R et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 10681070.
  • 74
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512516.